Latest 10-Q quarterly reports

Revvity, Inc. announced its second-quarter fiscal year 2026 results, showcasing a 1% revenue increase driven by its Diagnostics segment, while navigating a slight decrease in its Life Sciences segment.

Bolt Biotherapeutics, Inc. reported a net loss of $7.7 million for Q2 2026 and faces substantial doubt about its ability to continue as a going concern.

SINTX Technologies reported increased revenue for Q2 2026, but also highlighted substantial doubt about its ability to continue as a going concern, alongside significant operating losses.

iShares Bitcoin Premium Income ETF's Q2 2026 filing shows a net decrease in assets, primarily driven by unrealized losses on bitcoin and IBIT shares, partially offset by premiums from options written.

The iShares Staked Ethereum Trust ETF experienced a significant decline in net asset value per share during the second quarter of 2026, primarily driven by a decrease in the price of ether.

AN2 Therapeutics, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing continued investment in research and development, progress in clinical trials for epetraborole and AN2-502998, and a strong cash position.

Velo3D, Inc. filed its Q2 2026 10-Q, showing significant revenue growth but also substantial operating losses and a continued going concern warning, despite recent capital raises.

United States Antimony Corporation reported a net loss for the second quarter of 2026, with revenues declining significantly in its primary antimony segment, though its zeolite business showed strong growth.

Public Policy Holding Company reported a 7.3% increase in Q2 revenue to $52.1 million, driven by acquisitions and organic growth, while net losses narrowed.

Spectral AI, Inc. announced its Q2 2026 financial results, highlighting FDA De Novo classification for its DeepView System, while revenue declined and net loss widened.

High Roller Technologies, Inc. filed its Form 10-Q for the period ended June 30, 2026, reporting a substantial decrease in net gaming revenue and an increased net loss, alongside progress in securing a prediction market license.

Gladstone Land Corporation's Q2 2026 Form 10-Q filing reveals a net loss of $12.8 million for the six months ended June 30, 2026, a significant increase from the prior year, alongside a decrease in total lease revenues.

Cardiff Oncology's Q2 2026 report highlights ongoing litigation with NMS, substantial doubt about its going concern status, and a registered direct offering to raise capital, alongside promising clinical trial updates for onvansertib.

Smart Sand, Inc. announced a substantial increase in revenue and gross profit for the second quarter of 2026, driven by higher sales volumes and slightly improved pricing.

SELLAS Life Sciences Group reports increased cash reserves and positive clinical trial developments for its cancer therapeutics, alongside continued operational losses.

Worksport Ltd. reported increased net sales for the second quarter of 2026, but also a widening net loss and significant cash burn, raising concerns about its going concern status.

Kalaris Therapeutics, Inc. filed its Q2 2026 Form 10-Q, detailing continued operational losses and a strong reliance on future financing, while advancing its lead drug candidate TH103.

Hemab Therapeutics Holdings, Inc. filed its Q2 2026 Form 10-Q, detailing continued investment in R&D, progress in clinical trials for sutacimig and HMB-002, and a substantial cash position post-IPO.

Helios Technologies announces robust Q2 2026 results with significant increases in net sales, gross profit, and operating income, driven by strong performance in both Hydraulics and Electronics segments.

Flanigans Enterprises, Inc. announced a significant increase in revenue and net income for the third quarter ended June 27, 2026, driven by price increases and higher customer traffic.

Purple Innovation, Inc. reported a net loss of $3.2 million for Q2 2026, with revenues down 6.5% year-over-year, while acknowledging substantial doubt about its ability to continue as a going concern.

LataMed AI Corp. reported no revenue and significant operating losses for the six months ended June 30, 2026, raising substantial doubt about its ability to continue as a going concern.

Golden Growers Cooperative filed its Form 10-Q for the quarter ended June 30, 2026, reporting a decrease in corn revenue and net income, while also detailing progress on its approved Plan of Liquidation and Dissolution.

Momentus Inc. filed its Q2 2026 10-Q, detailing a significant increase in revenue and substantial capital raised, but also reporting a widening net loss and increased operating expenses.

Ambiq Micro reports a substantial 89.7% increase in net sales for the quarter ended June 30, 2026, driven by new product launches and customer adoption, while continuing to invest heavily in R&D.

PLAYSTUDIOS, Inc. announced its Q2 2026 financial results, showing a 7.3% decrease in net revenue and a significant widening of its net loss compared to the prior year period.

Independence Power Holdings, Inc. filed its Q2 2026 Form 10-Q, detailing significant net losses and no current revenue, while highlighting progress in asset management contracts and a secured note receivable.

Sentient Brands Holdings Inc. reported increased revenue for Q2 2026, but continued to incur net losses and faces substantial doubt regarding its ability to continue as a going concern.

Osprey Bitcoin Trust experienced a significant decrease in net assets for Q2 2026, primarily due to a substantial unrealized loss on its Bitcoin holdings.

Magnolia Bancorp, Inc. reported a net loss for the six months ended June 30, 2026, with total assets and deposits decreasing, though net interest income saw a modest increase.